Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study

Authors

Jesus Berdeja, Sarah Cannon Research Institute
Sundar Jagannath, Mount Sinai Hospital
Jeffrey Zonder, Wayne State University
Ashraf Badros, University of Maryland at Baltimore
Jonathan L. Kaufman, Emory University
Robert Manges, Investigative Clinical Research of Indiana
Manish Gupta, Bristol-Myers Squibb
Amol Tendolkar, Bristol-Myers Squibb
Mark Lynch, Bristol-Myers Squibb
Eric Bleickardt, Bristol-Myers Squibb
Prashni Paliwal, Bristol-Myers Squibb
Ravi Vij, Washington University School of Medicine in St. Louis

Journal

Clinical lymphoma myeloma and leukemia

Publication Date

2016

Volume

16

Issue

3

Inclusive Pages

129-138

Document Type

Open Access Publication

DOI

10.1016/j.clml.2015.12.007

Rights and Permissions

Berdeja J, et al (2016) Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. Clinical Lymphoma Myeloma and Leukemia, 16(3): 129-138. http://dx.doi.org/10.1016/j.clml.2015.12.007 2152-2650/Copyright 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Berdeja, Jesus; Jagannath, Sundar; Zonder, Jeffrey; Badros, Ashraf; Kaufman, Jonathan L.; Manges, Robert; Gupta, Manish; Tendolkar, Amol; Lynch, Mark; Bleickardt, Eric; Paliwal, Prashni; and Vij, Ravi, "Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study." Clinical lymphoma myeloma and leukemia. 16, 3. 129-138. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5593